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Summary
Objectives: The addition of cladribine to the standard regimen consisting of daunorubicin and
cytarabine has been reported to increase the efficacy of induction therapy in acute myeloid
leukemia (AML). The goal of this study was to determine the effect of this modification on the
incidence and spectrum of infectious complications.
Methods: Case report formsof 309patientswith newly diagnosedAMLwhohadbeenenrolled in the
prospective, randomized ‘DAC-7 vs. DA-7’ trial were reviewed. The frequency, etiology, localiza-
tion, severity, and outcome of infections were compared for patients receiving only daunorubicin
and cytarabine (DA-7) and those additionally treated with cladribine (DAC-7).
Results: A total of 443 febrile episodes were reported with no significant difference between the
treatment groups. A trend towards a higher frequency of bacteremias was observed among DA-7
patients compared to those in the DAC-7 group (31% vs. 21%; p = 0.08). The treatment arms did not
differ in terms of the distribution of the isolated Gram-positive, Gram-negative, fungal, and viral
organisms. However, when bacteremias were considered, Gram-positive blood cultures tended to
bemore frequent in the DA-7 compared to the DAC-7 group (16% vs. 8.5%; p = 0.07). This difference
reached statistical significance when major blood bacteremias were analyzed separately (13% vs.
5%; p = 0.02). Complete recovery from infections was observed in the majority of patients across
both treatment arms and no significant differencewas noted regarding infection-relatedmortality.
Conclusions: The addition of cladribine to standard induction chemotherapy has no impact on the
incidence and spectrum of infectious complications in newly diagnosed AML patients.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Patients with acute myeloid leukemia (AML) who undergo
intensive chemotherapy are at high risk for infectious com-
plications. Serious, life-threatening infections remain a
major cause of morbidity and mortality in this group of
patients.1 Several risk factors, mainly profound neutropenia
with a neutrophil count <0.1  109/l lasting more than 10
days, have been reported to increase the susceptibility to
infections in AML patients.1,2 In addition, other risk factors
such as impaired cellular and humoral immunity caused by
the underlying disease, severe mucositis, the degree of
hemorrhagic diathesis of skin and mucosal tissue, as well
as a number of skin-penetrating venous catheters are con-
sidered to predispose to infections.2—4
An induction chemotherapy consisting of daunorubicin
(DNR) for 3 days and cytarabine (Ara-C) for 7 days (DA-7
regimen) remains the standard first-line treatment in newly
diagnosed AML patients aged less than 60 years.5—7 The
results of AML therapy have improved in recent years due
to the intensification of Ara-C dose and the application of
new drugs to the induction treatment.8,9 Purine nucleoside
analogs (PNAs), such as cladribine and fludarabine, com-
monly used in the therapy of indolent lymphoid disorders,
have recently been introduced in the therapy of myeloid
malignancies.7,10—13 The immunosuppressive effect of PNAs
as well as the increased incidence of related infections have
been reported for patients with lymphoproliferative disor-
ders.14—22 The pathogenesis of this phenomenon seems to be
complex, multifactorial, and only partly understood. It is
known that PNAs can induce severe, prolonged immunosup-
pression due to long-lasting defects in cell-mediated immu-
nity with a decrease in the CD4+/CD8+ ratio. The PNA
therapy may also result in bone marrow suppression with
prolonged neutropenia, anemia, and thrombocytopenia.14—
18 In contrast, for AML patients data are scarce, since the
majority of published studies have mainly focused on PNAefficacy.7,10—13,23—27 In a previous study we demonstrated
that the addition of cladribine (2-CdA) to the DA-7 induction
regimen increased the efficacy of chemotherapy, resulting in
a higher complete remission rate observed after a single
course of treatment.7 However, until now, it has not been
determined whether this enhanced anti-leukemic effect is
associated with an increased incidence of infectious com-
plications. Therefore, verification of this hypothesis was the
scope of the current study. We addressed the question of
whether or not the addition of 2-CdA to the DA-7 regimen
influences the incidence and spectrum of infections during
the period of induction chemotherapy in newly diagnosed
AML patients.
Patients and methods
Study design
We reviewed the case report forms of 309 patients with
newly diagnosed AML who had been enrolled in the prospec-
tive, multicenter, randomized ‘DAC-7 vs. DA-7’ trial
betweenMay 1999 and June 2002.7 This studywas performed
in 11 centers of the Polish Adult Leukemia Group (PALG) and
was approved by the local ethics committees. Informed
consent was obtained from all patients, and patient con-
fidentiality was preserved in accordance with the Polish
regulations for studies of human subjects. Inclusion criteria
for the ‘DAC-7 vs. DA-7’ protocol were as follows: (1) AML
diagnosis established according to the French—American—
British (FAB) classification, (2) immune phenotyping per-
formed, and (3) age 16—60 years. Patients with FAB M3
subtype confirmed by promyelocytic leukemia (PML)/reti-
noic acid receptor-alpha (RAR-a) rearrangement and/or
t(15;17), as well as those with poor performance status
(Karnofsky index <40%), preceding chemo- or radiotherapy,
severe organ impairment, or pregnancy were not eligible for
the study.
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Patients were centrally randomized to one of the two follow-
ing induction treatment arms: (1) DAC-7, which consisted of
DNR 60 mg/m2 IV on days 1—3, Ara-C 200 mg/m2 CV (central
venous) on days 1—7, and cladribine (Biodribin, Bioton, War-
saw, Poland) 5 mg/m2 IV on days 1—5, and (2) DA-7, which
consisted of DNR and Ara-C in the same schedule without
cladribine. The comparison of the efficacy of the two induc-
tion regimens was the subject of a previous report.7
Antimicrobial and supportive therapy were given to the
patients according to commonly accepted guidelines.28 In the
case of the appearance of febrile episodes or infection
symptoms, empirical antimicrobial therapy was administered
according to the local variations in the frequency of isolated
pathogens and their drug-resistance pattern. Empirical first-
line antibiotic therapies were categorized into two groups:
monotherapy consisted of cephalosporin, penicillin, or car-
bapenem; and two-drug therapy comprised cephalosporin/
anti-pseudomonal penicillin/carbapenem + aminoglycoside
or ciprofloxacin + amoxicillin—clavulanate. Vancomycin was
added, if fever persisted for 48—72 hours and at least one of
the following clinical findings was met: clinically suspected
serious catheter-related infections, known colonization with
penicillin- and cephalosporin-resistant pneumococci or
methicillin-resistant Staphylococcus aureus, positive blood
cultures for Gram-positive bacteria before the final identi-
fication, hypotension or other evidence of cardiovascular
impairment.29 Amphotericin B was given empirically if the
patient did not respond to antibiotic therapy within 5 days.
Empirical therapy was given to those febrile patients for
whom there was yet no microbiological explanation for fever.
Cultures from blood and other suspected sites of infection
were collected from all febrile patients. Modifications of the
antibiotic therapy were made on the basis of results of
cultures and susceptibilities of microorganisms to antimicro-
bial agents. All antibiotics were discontinued after the
patient had been afebrile for 3—5 days and neutrophil recov-
ery occurred.
Assessment of infection incidence
Each episode of fever or the presence of infection symptoms
was reviewed and the series of data were collected for each
discrete infection. Fever was considered as a single tem-
perature measurement of38.3 8C or38.0 8C over at least
1 hour, in the absence of obvious environmental causes.28,29
All suspected or documented infections were graded accord-
ing to the National Cancer Institute’s Common Toxicity
Criteria.
The causative agent, when one was identified, was clas-
sified as bacterial (Gram-positive, Gram-negative, or other),
fungal (Candida species, Aspergillus species, or other), or
viral (varicella zoster virus, herpes simplex virus).
The site of infection was classified as oral cavity infections
(stomatitis) and upper respiratory tract (pharyngitis, sinusi-
tis, rhinitis), lower respiratory tract (pneumonia or bronchi-
tis), gastrointestinal (GI) tract, urinary tract, blood
(bacteremia), skin and/or soft tissues, and other. Blood
cultures were categorized as monomicrobial or polymicro-
bial, the latter if more than one organism was isolated in the
same blood culture, or in a separate blood culture obtainedwithin 24 hours.30,31 Catheter-related bloodstream infec-
tions were defined as those infections in which at least
one of the following conditions was met: (1) fever
(>38.0 8C) with chills and rigors within 1 hour after catheter
flushing or manipulation; (2) isolation of a pathogen from a
blood culture drawn through the catheter, but not from
another blood culture drawn from a peripheral vein at the
same time; (3) isolation of the same pathogen from the
catheter tip and from blood; (4) isolation of the same organ-
ism both from blood and from purulent material drained from
the catheter exit site or from the subcutaneous tunnel.31,32
Fever of unknown origin (FUO) was defined as isolated fever
without an identifiable focus of infection. If the site of
infection was later defined in the clinical course of the
patient, the infection was categorized as being from that
site and not as an FUO.
Neutropenia was defined as an absolute neutrophil count
(ANC) less than 1.0  109/l.28,29 ANC was further categorized
according to whether theywere<0.5  109/l or<0.1  109/l
at the onset of febrile episodes. Laboratory data collected at
the time of infection appearance included white blood cell
(WBC) count, ANC defined as the number of segmented
neutrophils and bands, the lymphocyte count, and serum
creatinine concentration.
Assessment of infection outcome
The outcome of infections for each patient was determined
at the completion of the antimicrobial therapy. All patients
who died of infection were classified as a failure. Complete
response to infection was defined as complete resolution of
all clinical and microbiological signs and symptoms of infec-
tion except of pneumonia. In the latter case, complete
response was defined as resolution of all symptoms and
significant improvement demonstrated by chest radiographs
or computed tomography (CT) scans. Partial response to
infection was classified as significant improvement of clinical
symptoms, negativity of all cultures, and/or partial regres-
sion of pulmonary infiltrates in chest roentgenography. Addi-
tionally, time of IV administration of antibiotics was used to
assess the effectiveness of antimicrobial therapy.
Statistical analysis
The incidence of infections during induction therapy was the
primary study end-point. Secondary end-points were: spec-
trum of infection (e.g., causative agent or site of infection),
absolute neutrophil and lymphocyte counts at the time of
infection occurrence, duration of anti-infectious therapy,
duration of supportive therapy with hematopoietic growth
factors, and infection outcome.
The two-tailed Pearson’s Chi-square test and Fisher’s
exact test were used to test the statistical significance of
differences in categorical data. For continuous variables the
Student’s t-test and the Mann—Whitney U-test were used
when appropriate. The significance level (alpha) of 0.05 was
used for all statistical tests, and no attempt was made to
adjust the alpha level for the large number of statistical tests
performed for this study. Thus, some tests recognized as
significant may be a result of chance alone, and this fact
should be kept in mind when interpreting as significant test
statistics with a p-value only slightly smaller than 0.05.
Table 1 Characteristics of 309 acute myeloid leukemia patients treated with DAC-7 or DA-7 induction chemotherapy
DAC-7 (N = 152) DA-7 (N = 157) p-Value
Age, years 44 (16—60) 45 (17—60) 0.6
Sex, male/female 80/72 78/79 0.6
AML subtypes
M0 5 (3.3) 6 (3.8) 1.0
M1 36 (23.7) 35 (22.3)
M2 41 (27.0) 47 (29.9)
M4 53 (34.9) 52 (33.1)
M5 12 (7.9) 12 (7.6)
M6 4 (2.6) 4 (2.5)
M7 1 (0.6) 1 (0.6) 0.2
Central venous catheter 102 (67.1) 113 (72.0) 0.4
Creatinine concentration at infection manifestation (mg/dl) 0.86 (0.4—1.6) 0.9 (0.1—1.72) 0.1
WBC at infection manifestation  109/l 0.8 (0.1—191) 1.05 (0.1—286) 0.08
ANC at infection manifestation  109/l 0.1 (0—9.4) 0.2 (0—23)
Lymphocytes at infection manifestation  109/l 0.5 (0—19) 0.66 (0.04—37) 0.007
Results are median (range) or n (%).
AML, acute myeloid leukemia; M0, AML minimally differentiated; M1, AML without maturation; M2, AML with maturation; M4, acute
myelomonocytic leukemia; M5, acute monoblastic and monocytic leukemia; M6, acute erythroid leukemia; M7, acute megakaryoblastic
leukemia; WBC, white blood cell; ANC, absolute neutrophil count.
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Patient characteristics
Demographic and clinical data for 309 AML patients asses-
sable for infectious complications are presented in Table 1.
One hundred fifty-two patients were treated with DAC-7
induction chemotherapy and 157 patients received the DA-
7 regimen. The two treatment groups did not differ in terms
of age, gender, AML subtypes, preceding myelodysplastic
syndrome (MDS), the proportion of patients with a central
venous catheter, as well as median of creatinine concentra-
tion, WBC and ANC counts at the time of infection occur-
rence. The majority of patients had a neutropenia with ANC
<1.0  109/l (86% in DAC-7 vs. 86% in DA-7; p = 1.0), or ANC
<0.5  109/l (75% in DAC-7 vs. 74% in DA-7; p = 0.8) at the
onset of infection; however, only a half of patients showed a
profound neutropenia with ANC <0.1  109/l (54% in DAC-7
vs. 45% in DA-7; p = 0.2). The median number of days with
grade IV neutropenia was 18 (range 7—37) in the DAC-7 group
and 19 (range 5—34) in the DA-7 group ( p = 0.1). The patients
who received the DAC-7 regimen presented significantly
more profound lymphocytopenia compared to those treated
with DA-7 chemotherapy at the time of infection manifesta-Table 2 Frequency of infections among acute myeloid leukemia
DAC-
All in
Total number of infections 220
Number of patients with any infection (%) 141 (
Mean number of infections per patient 1.44
Majo
Total number of major infections 76
Number of patients with a major infection (%) 64 (4
Mean number of major infections per patient 0.53tion ( p = 0.007) (Table 1). Data concerning the duration of
lymphocytopenia were not collected during this study.
Prophylactic antibacterial antibiotics were administered
to 224 (72%) of all AML patients starting on the first day of
chemotherapy and stopping after the recovery of ANC
>0.5  109/l. Of these patients, 49% received trimetho-
prim—sulfamethoxazole, 26% penicillins, and 20% of patients
received quinolones. There were no differences in the usage
of antibacterial prophylaxis ( p = 0.8) or the type of antibio-
tics used ( p = 0.8) between the DAC-7 and DA-7 patients. The
majority of patients (n = 283, 92%) received antifungal pro-
phylaxis. Azoles, mainly fluconazole, were administered to
90% of these subjects. Similarly, no differences were
observed in the usage of antifungal prophylaxis ( p = 0.6)
or the type of antifungal drugs used ( p = 1.0) between
patients treated with the DAC-7 and DA-7 regimens.
Infection incidence
A total of 443 febrile episodes and infections occurred in 309
patients over the induction treatment period with the same
frequency in DAC-7 and DA-7 patients (93% vs. 90%; p = 0.4).
The mean number of infections per patient was similar in the
two treatment arms (Table 2). Over the induction treatmentpatients according to the treatment arm
7 (N = 152) DA-7 (N = 157) p-Value
fections
223
93) 141 (90) 0.4
 0.77 1.40  0.76 0.9
r infections
92
2) 68 (43) 0.7
 0.65 0.64  0.76 0.3
Table 3 Site of infection in acute myeloid leukemia patients according to the treatment arm
All infections Major infections
Patients with at least one infection, n (%) Patients with at least one infection, n (%)
DAC-7 DA-7 p-Value DAC-7 DA-7 p-Value
Oral cavity 44 (31) 41 (29) 0.8 9 (6) 7 (5) 0.8
Upper respiratory tract 22 (16) 20 (14) 0.9 3 (2) 1 (0.7) 0.6
Lower respiratory tract 43 (30) 37 (26) 0.5 23 (16) 27 (19) 0.6
Gastrointestinal tract 9 (6) 11 (8) 0.8 4 (3) 5 (3.5) 1.0
Urinary tract 5 (3.5) 3 (2) 0.7 1 (0.7) 1 (0.7) 1.0
Blood 30 (21) 44 (31) 0.08 23 (16) 38 (27) 0.04
Skin/soft tissue 9 (6) 13 (9) 0.5 0 0 -
FUO 52 (37) 45 (32) 0.4 11 (8) 8 (6) 0.6
Venous catheter 4 (3) 7 (5) 0.5 2 (1) 3 (2) 1.0
Other sites 2 (1) 2 (1) 1.0 0 2 (1) 0.5
FUO, fever of unknown origin.
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World Health Organization classification) developed with the
same frequency in patients treated with the DAC-7 and DA-7
regimens (42% vs. 43%; p = 0.7). There was no significant
difference between the groups in terms of the number of
major infections (Table 2).
Site of infection
The sites of all infectious complications and major infections
are listed in Table 3. Across the two treatment arms, infec-
tions of the oral cavity and upper respiratory tract were most
frequent and developed in 47% of DAC-7 and 43% of DA-7
patients ( p = 0.8). More than one-third of patients from both
groups developed FUO (37% in the DAC-7 arm vs. 32% in the
DA-7 arm; p = 0.4). Eighty cases of lower respiratory tract
infection, mainly pneumonias, were observed during the
induction chemotherapy period, with similar frequency in
both groups (30% in DAC-7 vs. 26% in DA-7; p = 0.5). The rate
of positive results of blood cultures was 26% in all AML
patients during the induction treatment period. Overall,
74 episodes of bacteremia were reported and a trend towards
a higher incidence was observed among DA-7 patients com-
pared to DAC-7 patients (31% vs. 21%; p = 0.08). In the
analysis restricted solely to major infectious complications,Table 4 Causative microorganisms identified during infections in
All infections
Patients with at least one inf
DAC-7 DA-7
Gram-positive bacteria 29 (20.5) 36 (25.5)
Gram-negative bacteria 14 (10) 22 (16)
Polymicrobial bacteria 19 (13) 12 (8.5)
Anaerobic bacteria 2 (1) 3 (2)
Mycobacterium tuberculosis 0 1 (0.7)
Candida species 21 (15) 15 (11)
Aspergillus species 5 (3.5) 2 (1)
Varicella zoster/herpes
simplex virus
16 (11) 17 (12)the difference in the incidence of bacteremia was marginally
significant (27% vs. 16%; p = 0.04). Of 74 bacteremia epi-
sodes, 50 (67%) occurred in patients fitted with a central
venous catheter. Catheter-related infections accounted for
11 of 50 (22%) bacteremia episodes. There was no difference
in the proportion of catheter-related infections according to
the treatment regimen (3% in DAC-7 vs. 5% in DA-7; p = 0.5).
Causative agent
A causative agent of infection was documented in 214 (48%)
of 443 febrile episodes, and in 130 (77%) of the major
infections (Table 4). Of the 214 episodes, 65 (30%) were
due to Gram-positive bacteria, 36 (17%) to Gram-negative
bacteria, and 31 (14%) were polymicrobial infections. In
addition, 43 episodes (20%) were caused by proven fungal
infections. Of these fungal infections, 36 (84%) were caused
by Candida species, and only seven (16%) episodes were due
to Aspergillus species. In the study population, 33 (15%) viral
infections were observed, and the majority of them were
caused by herpesvirus. As shown in Table 4, there were no
statistically significant differences in the distribution of
Gram-positive, Gram-negative, fungal, or viral organisms
among patients treated with the DAC-7 or DA-7 regimen.
However, a trend towards a higher incidence of major Gram-acute myeloid leukemia patients
Major infections
ection, n (%) Patients with at least one infection, n (%)
p-Value DAC-7 DA-7 p-Value
0.4 15 (11) 26 (18) 0.09
0.2 9 (6) 15 (11) 0.3
0.2 13 (9) 9 (6) 0.5
1.0 2 (1) 1 (0.7) 1.0
1.0 0 1 (0.7) 1.0
0.4 11 (8) 9 (6) 0.8
0.4 5 (3.5) 1 (0.7) 0.2
1.0 8 (6) 5 (3.5) 0.6
Table 5 Frequency of any bacteremia or fungemia in acute myeloid leukemia patients according to the treatment arm
All infections Major infections
Patients with at least one infection, n (%) Patients with at least one infection, n (%)
DAC-7 DA-7 p-Value DAC-7 DA-7 p-Value
Gram-positive bacteremia 12 (8.5) 23 (16) 0.07 7 (5) 19 (13) 0.02
Gram-negative bacteremia 6 (4) 11 (8) 0.3 6 (4) 9 (6) 0.6
Polymicrobial bacteremia 10 (7) 7 (5) 0.6 8 (6) 7 (5) 1.0
Fungemia 2 (1) 3 (2) 1.0 2 (1) 3 (2) 1.0
Infectious complications in patients with AML e137positive infections in patients receiving the DA-7 regimen
compared to those treated with the DAC-7 regimen
was observed. One case of infection due to Mycobacterium
tuberculosis was reported in a patient treated with DA-7
chemotherapy.
A separate analysis was conducted for episodes with
positive blood cultures (Table 5). Microbiological analysis
revealed that Gram-positive cocci caused 47% of bactere-
mias, Gram-negative rods caused 23% of bacteremias, and
23% of bacteremias were polymicrobial. Five episodes of
fungemia (7%) were observed in AML patients during the
induction treatment period. All fungemias were caused by
Candida species. Comparing the two treatment arms, Gram-
positive blood cultures were reported more frequently in
patients treated with the DA-7 regimen compared to those
receiving DAC-7 therapy, however the difference was not
statistically significant. This tendency was more pronounced
for major infections analyzed separately (13% vs. 5%;
p = 0.02). The detailed distribution of organisms in the 74Table 6 Distribution of organisms among acute myeloid leukemia p
arm
Patients w
Organisms DAC-7 (n =
Gram-positive organisms
Staphylococcus aureus
Methicillin-susceptible 1 (3)
Methicillin-resistant 2 (7)
Coagulase-negative Staphylococcus
Methicillin-susceptible 3 (10)
Methicillin-resistant 4 (13)
Enterococcus species 2 (7)
Corynebacterium species 0
Gram-negative organisms
Escherichia coli 1 (3)
Pseudomonas species 1 (3)
Klebsiella species 1 (3)
Enterobacter species 0
Acinetobacter species 2 (7)
Serratia marcescens 1 (3)
Polymicrobial 10 (33)
Fungi
Candida species 2 (7)episodes of bacteremia and fungemia is shown in Table 6.
Across the two treatment arms, coagulase-negative staphy-
lococci were the most frequently isolated pathogens (21/74;
28%), followed by polymicrobial organisms (17/74; 23%) and
Staphylococcus aureus (7/74; 9%). Other pathogens were
isolated with similar frequencies, including enterococci
(5/74; 7%), Pseudomonas species (5/74; 7%), and Candida
species (5/74; 7%).
Infection outcome
Complete recovery from infectious complications was
observed in themajority of patients across the two treatment
arms (84% in the DAC-7 group and 84% in the DA-7 group;
Table 7). During the induction treatment period, 31 (11%)
patients died due to infectious complications. They did not
respond to antimicrobial therapies and the majority devel-
oped septic shock. Bacteremia episodes were complicated by
septic shock in 14 patients, with a similar distribution in bothatients with positive blood cultures according to the treatment
ith at least one episode of bacteremia or fungemia
30) DA-7 (n = 44) p-Value
2 (4.5) 1.0
2 (4.5) 1.0
4 (9) 1.0
10 (23) 0.4
3 (7) 1.0
2 (4.5) 0.5
2 (4.5) 1.0
4 (8.5) 0.6
1 (2) 1.0
2 (4.5) 0.5
2 (4.5) 1.0
0 1.0
7 (16) 0.1
3 (7) 1.0
Table 7 Infection outcome in acute myeloid leukemia patients according to the treatment arm
Response to antimicrobial therapy Patients with at least one infection, n (%) Patients with at least one major infection,
n (%)
DAC-7 (n = 141) DA-7 (n = 141) p-Value DAC-7 (n = 64) DA-7 (n = 68) p-Value
Complete response 119 (84) 119 (84) 0.2 45 (70) 51 (75) 0.3
Partial response 2 (1) 6 (4) 2 (3) 5 (7)
Infection-related death 18 (13) 13 (9) 17 (27) 12 (18)
e138 E. Lech-Maranda et al.treatment arms. All these patients had neutropenia
<1.0  109/l at the onset of infection. No significant differ-
ence in infection-related mortality was observed among the
two treatment groups.
Five patients (two subjects from the DAC-7 group and
three from the DA-7 group) were not considered for infection
outcome assessment because they died due to other com-
plications, including four with central nervous system hemor-
rhage and one patient with myocardial infarction.
Two hundred eighty-two patients (91%) required empirical
first-line antibiotic therapy. Of these, 233 (83%) required the
addition of a new antibacterial drug or complete replace-
ment of the empirical first-line regimen. No difference was
noted with regard to the necessity for first-line antibiotic
change between patients receiving DAC-7 or DA-7 (78% vs.
76%; p = 0.8). Of 282 patients who had received antimicrobial
therapy, empirical antifungal therapy was given to 123 (44%)
patients. Similarly, there was no statistical difference con-
cerning the application of antifungal antibiotics among DAC-7
and DA-7 patients (44% vs. 40%; p = 0.4). Themedian duration
of antimicrobial IV therapy was marginally longer in the DAC-
7 patients than the DA-7 patients (25 days, range 0—62 days
and 24 days, range 0—74 days, respectively; p = 0.054). In the
separate analysis of major infections, the duration of IV
antibiotic therapy was similar in both treatment arms (28
days, range 4—62 days in the DAC-7 group and 27 days, range
6—74 days in the DA-7 group; p = 0.2).
The use of supportive therapy with hematopoietic growth
factors was comparable in both study groups. Thirty-six
patients (25%) in the DAC-7 arm and 33 patients (23%) in
the DA-7 arm received granulocyte colony-stimulating factor
(G-CSF) to enhance ANC recovery during infectious complica-
tions. Themedian therapy with G-CSF was 7 days (range 1—16
days) in the DAC-7 group compared to 6 days (range 2—20
days) in the DA-7 group ( p = 0.6).
Discussion
The results of the present study did not reveal any significant
differences regarding the frequency, severity, or spectrum of
infectious complications in AML patients treated with DA-7 or
DAC-7 regimens during the period of induction chemother-
apy. Additionally, the microbiological analysis of overall
infection episodes showed no significant differences in the
distribution of Gram-positive, Gram-negative, fungal, or
viral organisms isolated from patients treated with DAC-7
or DA-7 regimens. Since this was a retrospective study, any
assumption about the number of patients in the particular
groups was not performed. With respect to this, the lack of
power as a potential source of error should be taken into
consideration. Interestingly, the only difference noted wasthe incidence of bacteremias: Gram-positive bacteria were
unexpectedly reported more frequently in patients receiving
the DA-7 regimen compared to those receiving the DAC-7
regimen. This difference reached statistical significance
when major infections were analyzed separately. However,
it should be underlined that these results also need to be
interpreted with caution due to the large number of multiple
statistical comparisons performed for this study.
The overall incidence as well as profile of infections in the
whole study population was consistent with previously pub-
lished reports on AML patients undergoing induction ther-
apy.6,33—36 In our study, 91% of patients presented any
infectious complication, and serious infections were
observed in approximately 43% of patients. Over 80% of
patients with neutropenia after chemotherapy have been
reported to develop fever.2,28,29 As the source of febrile
episodes is often difficult to identify, about 30% of infections
were considered as FUO.2 In the present study, at least one
site of fever was identified in 78% of all febrile episodes,
whereas 22% of infectious complications were expressed as
FUO. Our results are comparable with those observed by
Madani, who identified a source of fever in 81% of infections
and 19% of febrile episodes classified as FUO.33 The author
showed that in AML patients, the most common cause of
fever was mucositis followed by pneumonia, central venous
catheter infection, neutropenic enterocolitis, and invasive
fungal disease.33 In our study, the distribution of infection
sites was similar; the oral cavity, mainly related to mucosi-
tis, and the upper respiratory tract were the most frequent
sites of infection, followed by lower respiratory tract invol-
vement. Infections of the gastrointestinal tract and central
venous catheter, as well as skin and soft tissues were
observed less frequently in our patients. Bloodstream infec-
tions in AML patients undergoing chemotherapy were
reported to be associated with 38% of febrile episodes.33
In the present study, bacteremias were related to 17% (74/
443) of all febrile episodes, and the incidence of blood-
stream infections among AML patients reached 26% (74/
282). This is in line with results reported by Klastersky
et al. who observed that 23% of cancer patients with febrile
neutropenia developed bacteremia.37
Over the last two decades, a shift towards a higher
frequency of Gram-positive infections has been observed,
whereas Gram-negative pathogens are less frequently iso-
lated from neutropenic patients with cancer.2,29,38,39 This
may be as a result, in part, of the use of more intensive
chemotherapy, particularly high dose cytarabine, which
has contributed to an increased incidence of severe muco-
sitis, profound and prolonged neutropenia, the common
application of central venous catheters, and the use of
antibiotic prophylaxis, particularly co-trimoxazole and
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in our study remains in line with the observations of other
investigators.13,34,35 Bacterial organisms were proven in
76% (138/181) of all microbiologically documented infec-
tions. Among these pathogens, Gram-positive bacteria,
especially coagulase-negative staphylococci and entero-
cocci, were isolated most frequently. However, we noted
an increased incidence of polymicrobial blood cultures as
compared to other reports.37 Viral infections, mainly clini-
cally documented, accounted for 7.5% (33/443) of all
febrile episodes in this study. The majority of them were
caused by herpesvirus and no case of cytomegalovirus
infection was recorded. Fungal infections accounted for
approximately 10% (43/443) of all febrile episodes. Can-
dida species were the most frequently isolated fungi and
caused mainly oral candidiasis. The frequency of fungemia
observed in our study was slightly lower (7%; 5/74) com-
pared to that reported by Madani (10.6%).33 It is known
that microbiological confirmation of fungal species pre-
sents major clinical problems.36 It cannot be ruled out that
the proportion of fungal infections among our patients
would be higher if more invasive diagnostic methods were
used to identify the causative agent of infection. However,
such diagnostic methods may be difficult to conduct in AML
patients, especially in those with profound neutropenia
and thrombocytopenia at the onset of infection.
The administration of standard induction chemotherapy
consisting of daunorubicin and cytarabine results in pro-
found neutropenia and lymphocytopenia in AML patients.
It may be hypothesized that the incorporation of another
myelo- and immunosuppressive agent such as cladribine
could provide additional risk for life-threatening complica-
tions. It has also been reported that chemotherapy regimens
consisting of high-dose cytarabine with PNAs lead to pro-
found neutropenia and T-cell depletion, and in consequence
contribute to an increased risk for invasive fungal and viral
infections.37 Moreover, the use of PNAs may introduce the
potential for a new spectrum of infectious complica-
tions.17,18 Infections caused by Pneumocystis carinii, Lis-
teria monocytogenes, cytomegalovirus, herpes simplex and
varicella zoster virus, as well asMycobacterium tuberculosis
and fungi have frequently been observed in patients treated
with PNAs.17—20 In our study, although patients treated with
cladribine presentedmore profound lymphocytopenia at the
onset of infection, the frequency and spectrum of infectious
complications as well as the infection outcome were com-
parable in both treatment groups. Our findings could prob-
ably be explained by the fact that DAC-7 and DA-7 patients
did not differ significantly in terms of duration of neutro-
penia, which seems to be the most important factor deter-
mining susceptibility to infections in AML patients
undergoing induction therapy.7
We conclude that the incorporation of cladribine into the
induction regimen containing daunorubicin and cytarabine
does not provide additional risk for infections in newly
diagnosed AML patients, including the incidence and spec-
trum of etiological factors as well as their severity and
infection outcome, especially in the context of the duration
of anti-infectious and supportive therapy. However, taking
into account the retrospective nature of this study and
relatively low numbers of cases analyzed, a prospective
multicenter study is required to confirm our results. Theprecise analysis of the spectrum of infections as well as
microorganisms responsible for febrile episodes may help
in the prevention and therapeutic management of infectious
complications in AML patients.
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